Watch as investigators and families they study discuss dyskeratosis congenita, a rare and complex inherited cancer predisposition syndrome.
Dyskeratosis Congenita (DC) is a cancer-prone inherited bone marrow failure syndrome (IBMFS) caused by aberrant telomere biology. DCEG investigators in the Clinical Genetics Branch (CGB) showed that telomere length, as measured by flow cytometry-FISH was both sensitive and specific for distinguishing DC from healthy individuals and from those with other IBMFS.
Work at CGB has led to the discovery of three of the known causes of DC, TINF2, WRAP53, and RTEL1. DC can be inherited in X-linked (DKC1), autosomal dominant (TERT, TERC, TINF2, RTEL1), and autosomal recessive (TERT, NHP2, NOP10, CTC1, WRAP53, and RTEL1) patterns, or can arise due to a de novo germline mutation. However, approximately 40% of patients with DC do not yet have an identified causative mutation. Consequently, discovery of new high-penetrance susceptibility genes as well as low-penetrance genetic modifiers of the major genes, is a major focus of this project.
This study also focuses on comprehensive, systematic clinical phenotyping of DC patients, aimed at refining our understanding of the features of this rare disorder. Investigators have identified novel ophthalmologic and dental abnormalities as part of the DC spectrum of abnormalities. These studies will provide more specific data on genotype-phenotype interactions and aid in diagnosis of DC.
In addition, DCEG investigators recently performed a quantitative analysis of the reported literature on DC-related malignancy, and published the first quantitative estimates of the risks of acute leukemia, squamous cell cancers of the skin, head/neck and anogenital region in this disorder. The cumulative cancer risk in DC patients is nearly as high as those seen in patients with Fanconi anemia.
For more information, contact Sharon Savage.